Rituxan (USA)
Mabthera (Worldwide)
Active substance: Rituximab
Manufacturer: Genentech (USA) / Roche (Worldwide)
Extract from the prescribing information:
"Rituxan administration can result in serious, including fatal infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion."
The above has been extracted from the Rituximab prescribing information on the Genentech webpages.